Investigators are exploring concurrent PARP inhibition and definitive regional radiotherapy in patients with metastatic invasive cervical cancer in an ongoing phase I/II study.
Original Article: Niraparib Plus Radiotherapy Explored in Metastatic Cervical Cancer